English | Español
Patient Daily | Apr 10, 2026

AbbVie maintains confidence in Skyrizi after FDA approval of Icotyde for plaque psoriasis
Patient Daily | Apr 10, 2026

Takeda restructuring could affect more than 600 US employees, company says
Patient Daily | Apr 10, 2026

Lilly and Baseline investigate GLP-1 drugs for substance use disorders as research grows
Patient Daily | Apr 10, 2026

Kardigan blood pressure drug advances after mixed Phase 2 trial results
Patient Daily | Apr 10, 2026

FDA expected to make key drug approval decisions in second quarter of 2026
Patient Daily | Apr 10, 2026

Kevin Tang returns as Aurinia CEO with $50 million offer for Kezar Life Sciences
Patient Daily | Apr 10, 2026

Study shows PSMA therapy can delay hormone treatment in prostate cancer patients
Patient Daily | Apr 10, 2026

Study finds inhaling disinfectant chemicals may cause lung injury in mice

Trending
+ Regulatory
Patient Daily | Apr 28, 2026

Archo Advocacy CEO Toresco on PBMs: 'PBMs profit from keeping prices high. Patients pay the spread'
+ Pharmaceuticals
Patient Daily | Apr 24, 2026

Washington Post Opinion Editor on 340B drug discounts: 'The program has become a profit-making venture for big businesses'
+ Regulatory
Patient Daily | Apr 29, 2026

USC Schaeffer Center's Sood on PBMs: 'If PBMs want to claim they save employers and patients billions, they should be willing to prove it'
+ Regulatory
Patient Daily | Apr 24, 2026

Steve Forbes on 340B program: Hospitals use it ‘to divert taxpayer-subsidized benefits for patients to unrelated interests’